Suppr超能文献

YES1激酶和酪氨酸磷酸化对OCT1活性的影响。

Influence of YES1 Kinase and Tyrosine Phosphorylation on the Activity of OCT1.

作者信息

Uddin Muhammad Erfan, Garrison Dominique A, Kim Kyeongmin, Jin Yan, Eisenmann Eric D, Huang Kevin M, Gibson Alice A, Hu Zeping, Sparreboom Alex, Hu Shuiying

机构信息

Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States.

School of Pharmaceutical Sciences, Tsinghua University, Beijing, China.

出版信息

Front Pharmacol. 2021 Mar 8;12:644342. doi: 10.3389/fphar.2021.644342. eCollection 2021.

Abstract

Organic cation transporter 1 (OCT1) is a transporter that regulates the hepatic uptake and subsequent elimination of diverse cationic compounds. Although OCT1 has been involved in drug-drug interactions and causes pharmacokinetic variability of many prescription drugs, details of the molecular mechanisms that regulate the activity of OCT1 remain incompletely understood. Based on an unbiased phospho-proteomics screen, we identified OCT1 as a tyrosine-phosphorylated transporter, and functional validation studies using genetic and pharmacological approaches revealed that OCT1 is highly sensitive to small molecules that target the protein kinase YES1, such as dasatinib. In addition, we found that dasatinib can inhibit hepatic OCT1 function in mice as evidenced from its ability to modulate levels of isobutyryl L-carnitine, a hepatic OCT1 biomarker identified from a targeted metabolomics analysis. These findings provide novel insight into the post-translational regulation of OCT1 and suggest that caution is warranted with polypharmacy regimes involving the combined use of OCT1 substrates and kinase inhibitors that target YES1.

摘要

有机阳离子转运体1(OCT1)是一种调节肝脏对多种阳离子化合物摄取及后续清除的转运体。尽管OCT1参与了药物相互作用并导致许多处方药的药代动力学变异性,但调节OCT1活性的分子机制细节仍未完全明确。基于无偏差的磷酸化蛋白质组学筛选,我们将OCT1鉴定为一种酪氨酸磷酸化的转运体,并且使用基因和药理学方法进行的功能验证研究表明,OCT1对靶向蛋白激酶YES1的小分子(如达沙替尼)高度敏感。此外,我们发现达沙替尼能够抑制小鼠肝脏中的OCT1功能,这从其调节异丁酰L-肉碱水平的能力得到证明,异丁酰L-肉碱是通过靶向代谢组学分析鉴定出的肝脏OCT1生物标志物。这些发现为OCT1的翻译后调控提供了新的见解,并表明在涉及联合使用OCT1底物和靶向YES1的激酶抑制剂的多药治疗方案中需要谨慎。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4d2/8006202/adffb810e6c2/fphar-12-644342-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验